Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05822583
Registration number
NCT05822583
Ethics application status
Date submitted
4/02/2023
Date registered
21/04/2023
Date last updated
15/08/2024
Titles & IDs
Public title
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial
Query!
Scientific title
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial
Query!
Secondary ID [1]
0
0
STRIVE
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Infection
0
0
0
0
Query!
Studies of infection and infectious agents
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - abatacept infusion
Treatment: Drugs - Placebo group
Experimental: active treatment group - Active treatment group (IV abatacept infusion, 10 mg/kg up to 1750 mg) + baseline IM
Placebo comparator: Control group - Placebo group (IV infusion of normal saline) + baseline IM
Treatment: Drugs: abatacept infusion
The dose of abatacept will be 10 mg/kg given as a single infusion on Day 0, with a maximum dose of 1,750 mg, so any participant with weight of \>175 kg will receive a dose of 1750 mg. + baseline IM (immune modulator)
Treatment: Drugs: Placebo group
Placebo group (IV infusion of normal saline) + baseline IM
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Days to Recovery Scale
Query!
Assessment method [1]
0
0
DRS-60 is a version of the STRIVE clinical recovery scale (CRS) which combines time to recovery with non-recovered clinical state and death to an ordinal outcome.0 indicates best results, 60 represents recovered on Day 60, with not recovered by Day 60 coded as 61 and death (worst outcome) as 62.
Query!
Timepoint [1]
0
0
60 days post-intervention
Query!
Secondary outcome [1]
0
0
time to sustained recovery though Day 60
Query!
Assessment method [1]
0
0
Time to sustained recovery is defined as being discharged from the index hospitalization, followed by being alive and home for 14 consecutive days prior to the end of follow-up
Query!
Timepoint [1]
0
0
baseline to day 60
Query!
Secondary outcome [2]
0
0
all-cause mortality though Day 60
Query!
Assessment method [2]
0
0
substantial attempts will be made to determine vital status through the end of follow-up by a combined approach of follow-up visits with the participant or proxy, chart review, and review of other available information sources.
Query!
Timepoint [2]
0
0
baseline to day 60
Query!
Secondary outcome [3]
0
0
time to progression
Query!
Assessment method [3]
0
0
will be defined by the study day on which a participant experiences a definite progression.
Definite progression is defined as a participant requiring HFNO, NIV, IMV, or ECMO therapy, OR, if HFNO is unavailable, a participant requiring =15 L/min conventional oxygen.
Probable progression is defined as a participant not meeting criteria for definite progression but requiring =10 L/min conventional oxygen, OR, a participant with an oxygen requirement that has increased by =4 L/min in the preceding 24 hours.
Query!
Timepoint [3]
0
0
baseline to day 60
Query!
Secondary outcome [4]
0
0
Three-category ordinal outcome
Query!
Assessment method [4]
0
0
assessed at Day 60, with categories "recovered (alive and at home at Day 60)", "alive and not recovered", and dead
Query!
Timepoint [4]
0
0
Day 60
Query!
Secondary outcome [5]
0
0
the pulmonary ordinal outcome
Query!
Assessment method [5]
0
0
categories defined as:
1. Can independently undertake usual activities with minimal or no symptoms
2. Symptomatic and currently unable to independently undertake usual activities but no need of supplemental oxygen (or not above premorbid requirements)
3. Supplemental oxygen \<4 liters/min (or \<4 liters/min above premorbid requirements)
4. Supplemental oxygen =4 liters/min (or =4 liters/min above premorbid requirements, but not high-flow oxygen)
5. Non-invasive ventilation or high-flow oxygen
6. Invasive ventilation, extracorporeal membrane oxygenation (ECMO), mechanical circulatory support, or new receipt of renal replacement therapy
7. Death
Query!
Timepoint [5]
0
0
Day 5, 14, and 28
Query!
Eligibility
Key inclusion criteria
* Confirmation of SARS-CoV2 infection by nucleic acid test (NAT) or equivalent non-NAT test [list of approved tests in the PIM] within 14 days of randomization.
* Requiring hospitalization for the management of COVID-19
* Has evidence of COVID-19 pneumonia (PNA) defined as either receiving supplementary oxygen =2L of low flow oxygen with evidence of airspace disease on chest imaging (X ray, computer tomography or ultrasound) OR receiving supplementary oxygen >2L and <10 L of low flow oxygen.
* Currently receiving or planned to receive (ordered) one IM drug (for example, a corticosteroid or baricitinib) as part of treatment of COVID-19 prior to randomization.
* Has started supplemental oxygen for the treatment of COVID-19 within the past 5 calendar days. Patients on home oxygen are eligible if current oxygen flow rate is increased from baseline and other above criteria are met.
* Investigator agrees that the pneumonia is due to COVID-19.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Oxygen requirement of =10L or more of low flow oxygen (or equivalent if using Venturi mask, etc), or requiring either HFNO, NIV, IMV, or ECMO.
* Participant has received more than one baseline IM for treatment of the current COVID-19 infection at time of trial enrollment. (Examples: corticosteroid, baricitinib, tocilizumab, anakinra, abatacept, or infliximab.)
* Participant anticipated to not meet all inclusion criteria within 24 hours of randomization in the opinion of the investigator.
* Allergy to investigational agent.
* Neutropenia (absolute neutrophil count <1000 cells/µL) (<1.0 x 10 3 /µL or <1.0 G/L) on most recent lab within 2 calendar days of randomization.
* Lymphopenia (absolute lymphocyte count <200 cells/µL) (<0.20 x 10 3 /µL or <0.20 G/L) on most recent lab within 2 calendar days of randomization.
* Known or suspected active or recent serious infection (bacterial, fungal, viral, or parasitic infection, excepting SARS-CoV-2) that in the opinion of the investigator could constitute a risk when taking investigational agent. Note: Broad spectrum empiric antibiotic usage does not exclude participation.
* Known or suspected history of untreated tuberculosis (TB). TB diagnosis may be suspected based on medical history and concomitant therapies that would suggest TB infection. Participants are also excluded if they have known, latent TB treated for less than 4 weeks with appropriate anti-tuberculosis therapy per local guidelines (by history only, no screening required).
* Have received any live vaccine (or live attenuated) within 3 months before screening or intend to receive a live vaccine (or live attenuated) during the trial. Use of prior non-live (inactivated) vaccinations is allowed for all participants, including any vaccine for COVID-19.
* Pre-existing immunomodulation or immunosuppression that meets any of the following: Participant has received abatacept for an indication other than COVID- 19 within 5 half-lives (65 days) of enrollment (Abatacept elimination half-life is 13.1 days.) Participant is receiving immune modulatory therapy for autoimmune, transplant management or another indication AND has one or more of the following: evidence of active infection (other than COVID-19) or has required reduction in their immune modulatory therapy in the preceding 6 months due to infectious complication (routine reduction as SOC is not an exclusion) or has required intensification in immunotherapy within the preceding 6 months due to organ rejection/worsening underlying disease status (e.g., intensification with an additional agent on top of usual immunosuppressive regimen)
* Participant has recently received or is anticipated to require immune modulatory agents for their underlying disease including chemotherapeutic treatments likely to induce neutropenia (<1.0 x 10 9 cells/µL) or lymphopenia (<1.0 x 10 9 cells/µL)
* Participant has untreated advanced HIV (known CD4 <200 in the past 6 months) AND is not established on antiretroviral therapy
* Pregnancy
* Breastfeeding
* Co-enrollment in other trials not predetermined to be compatible with this trial.
* In the investigator's judgment, the patient has any advanced organ dysfunction that would not make participation appropriate.
* The treating clinician expects inability to participate in trial procedures or participation would not be in the best interests of the patient.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
6/07/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/07/2025
Query!
Actual
Query!
Sample size
Target
1500
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Westmead Hospital (Site 612-058) - Westmead
Query!
Recruitment hospital [2]
0
0
Monash Health (612-009) - Clayton
Query!
Recruitment hospital [3]
0
0
Austin Health (612-020) - Heidelberg
Query!
Recruitment hospital [4]
0
0
The Alfred Hospital (612-017) - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [2]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [3]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [4]
0
0
3004 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
District of Columbia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Indiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kansas
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Massachusetts
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Michigan
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Minnesota
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Mississippi
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Missouri
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Nebraska
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New Hampshire
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New Jersey
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
New Mexico
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
New York
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
North Carolina
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Ohio
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Oregon
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Pennsylvania
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Rhode Island
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
South Carolina
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Tennessee
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Texas
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Utah
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Virginia
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Washington
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
West Virginia
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Wisconsin
Query!
Country [34]
0
0
Denmark
Query!
State/province [34]
0
0
C
Query!
Country [35]
0
0
Denmark
Query!
State/province [35]
0
0
Aalborg
Query!
Country [36]
0
0
Denmark
Query!
State/province [36]
0
0
Aarhus
Query!
Country [37]
0
0
Denmark
Query!
State/province [37]
0
0
Copenhagen
Query!
Country [38]
0
0
Denmark
Query!
State/province [38]
0
0
Hellerup
Query!
Country [39]
0
0
Denmark
Query!
State/province [39]
0
0
Hillerød
Query!
Country [40]
0
0
Denmark
Query!
State/province [40]
0
0
Hvidovre
Query!
Country [41]
0
0
Georgia
Query!
State/province [41]
0
0
Tbilisi
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Cologne
Query!
Country [43]
0
0
Greece
Query!
State/province [43]
0
0
Attica
Query!
Country [44]
0
0
Greece
Query!
State/province [44]
0
0
Evros
Query!
Country [45]
0
0
India
Query!
State/province [45]
0
0
Tamil Nadu
Query!
Country [46]
0
0
Korea, Republic of
Query!
State/province [46]
0
0
Seongnam
Query!
Country [47]
0
0
Korea, Republic of
Query!
State/province [47]
0
0
Seoul
Query!
Country [48]
0
0
Poland
Query!
State/province [48]
0
0
Warsaw
Query!
Country [49]
0
0
Spain
Query!
State/province [49]
0
0
Barcelona
Query!
Country [50]
0
0
Thailand
Query!
State/province [50]
0
0
Bangkok
Query!
Country [51]
0
0
Thailand
Query!
State/province [51]
0
0
Khon Kaen
Query!
Country [52]
0
0
Ukraine
Query!
State/province [52]
0
0
Ivano-Frankivs'k
Query!
Country [53]
0
0
Ukraine
Query!
State/province [53]
0
0
Kyiv
Query!
Country [54]
0
0
Ukraine
Query!
State/province [54]
0
0
Zhytomyr
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
University of Minnesota
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery as compared with placebo + SOC (placebo arm). For both groups, intensification of immunomodulation will be provided as part of SOC in case of signs of disease progression (patient requires high flow nasal oxygen (HFNO) or more support) and/or if the patient has rapidly increasing oxygen requirement.
Query!
Trial website
https://clinicaltrials.gov/study/NCT05822583
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Jens Lundgren, PhD
Query!
Address
0
0
University of Copenhagen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Cavan Reilly, PhD
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
612-624-9644
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT05822583
Download to PDF